[go: up one dir, main page]

GB1202148A - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
GB1202148A
GB1202148A GB1095768A GB1095768A GB1202148A GB 1202148 A GB1202148 A GB 1202148A GB 1095768 A GB1095768 A GB 1095768A GB 1095768 A GB1095768 A GB 1095768A GB 1202148 A GB1202148 A GB 1202148A
Authority
GB
United Kingdom
Prior art keywords
active ingredient
pharmaceutical compositions
compositions
thebainol
antitussives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1095768A
Inventor
Isao Seki
Hiromu Takagi
Shinsaku Kobayashi
Issei Iwai
Haruhiko Minakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Priority to GB1095768A priority Critical patent/GB1202148A/en
Publication of GB1202148A publication Critical patent/GB1202148A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1,202,148. Antitussives. SANKYO CO. Ltd. 6 March, 1968. No. 10957/68. Heading A5B. Antitussive pharmaceutical compositions comprise 14-hydroxy-dihydro-6-beta-thebainol- 4-methyl ether as active ingredient and comprise a sterile solution syrup or suspension for oral administration, a pressurised composition containing a liquified propellant or the active ingredient in admixture with a solid pharmaceutical carrier or diluent. The compositions may be administered orally as tablets optionally coated, powders, capsules or granules and the sterile solutions optionally contain preservatives and antibacterial agents.
GB1095768A 1968-03-06 1968-03-06 Pharmaceutical compositions Expired GB1202148A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1095768A GB1202148A (en) 1968-03-06 1968-03-06 Pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1095768A GB1202148A (en) 1968-03-06 1968-03-06 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GB1202148A true GB1202148A (en) 1970-08-12

Family

ID=9977425

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1095768A Expired GB1202148A (en) 1968-03-06 1968-03-06 Pharmaceutical compositions

Country Status (1)

Country Link
GB (1) GB1202148A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306575A1 (en) * 1987-09-10 1989-03-15 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US8003794B2 (en) 2005-05-25 2011-08-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US8247425B2 (en) 2008-09-30 2012-08-21 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8343992B2 (en) 2005-05-25 2013-01-01 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US8552025B2 (en) 2003-04-08 2013-10-08 Progenics Pharmaceuticals, Inc. Stable methylnaltrexone preparation
US9102680B2 (en) 2007-03-29 2015-08-11 Wyeth Llc Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US12303592B2 (en) 2006-08-04 2025-05-20 Wyeth, Llc Formulations for parenteral delivery of compounds and uses thereof

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306575A1 (en) * 1987-09-10 1989-03-15 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US8552025B2 (en) 2003-04-08 2013-10-08 Progenics Pharmaceuticals, Inc. Stable methylnaltrexone preparation
US10376584B2 (en) 2003-04-08 2019-08-13 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US9669096B2 (en) 2003-04-08 2017-06-06 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US8003794B2 (en) 2005-05-25 2011-08-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US8343992B2 (en) 2005-05-25 2013-01-01 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US9597327B2 (en) 2005-05-25 2017-03-21 Progenics Pharmaceuticals, Inc. Synthesis of (R)-N-methylnaltrexone
US8916581B2 (en) 2005-05-25 2014-12-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US12303592B2 (en) 2006-08-04 2025-05-20 Wyeth, Llc Formulations for parenteral delivery of compounds and uses thereof
US8853232B2 (en) 2007-03-29 2014-10-07 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US9879024B2 (en) 2007-03-29 2018-01-30 Progenics Pharmaceuticals., Inc. Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US9102680B2 (en) 2007-03-29 2015-08-11 Wyeth Llc Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US8772310B2 (en) 2007-03-29 2014-07-08 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8916706B2 (en) 2008-02-06 2014-12-23 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US9180125B2 (en) 2008-09-30 2015-11-10 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US8455644B2 (en) 2008-09-30 2013-06-04 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8420663B2 (en) 2008-09-30 2013-04-16 Wyeth Peripheral opioid receptor antagonists and uses thereof
US9724343B2 (en) 2008-09-30 2017-08-08 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US9492445B2 (en) 2008-09-30 2016-11-15 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US8822490B2 (en) 2008-09-30 2014-09-02 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8247425B2 (en) 2008-09-30 2012-08-21 Wyeth Peripheral opioid receptor antagonists and uses thereof

Similar Documents

Publication Publication Date Title
IE881916L (en) Press-coated dihydropyridine tablets
CA2030838A1 (en) Preparations containing l-carnitine
GB1204580A (en) Pharmaceutical dosage forms
GB1171691A (en) Lond-Acting Oral Carrier
GB1202148A (en) Pharmaceutical compositions
GB1458048A (en) Pharmaceutical composition
MY106371A (en) Oral pharmaceutical compositions in unit dosage form
GB1457546A (en) Pharmaceutical preparations comprising cephalosporin derivatives
GB1445995A (en) Pharmaceutical preparations comprising n-4-2-5-chloro-2-metho xybenzamidoethyl-phenylsulphonyl-n-cyclohexylurea and salts thereof
GB1442159A (en) Pharmaceutical compositions containing paracetamol
IE33207L (en) Pharmaceutical compositions containing diazacarbazole
GB1535778A (en) Compounds useful in treatment of unipolar depression
ZA714785B (en) A pharmaceutical composition containing a pharmaceutically active compound
GB1375806A (en)
GB1446237A (en) Pharmaceutical preparations containing pyrazolones
GB1454872A (en) Anticonvulsant
GB1287433A (en) Pharmaceutical compositions
GB1021070A (en) A new triazolone and a process for its preparation
GB1454390A (en) Nasal decongestants
GB1233150A (en)
GB1300486A (en) Compositions for the treatment of respiratory ailments in man
GB1251237A (en)
CA953715A (en) N(6)-(2,5-dimethylbenzyl)-2-chloroadenosine derivatives, process for their preparation and pharmaceutical compositions containing the same
IL32930A0 (en) Controlled-release pharmaceutical compositions containing a polymer for chemisorbing the active drug,and a carboxylic acid
GB1446615A (en) Pharmaceutical compositions containing an anti-allergy drug

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee